The Patent Finder

Merck Canada Inc.

16 patents currently held · Updated Nov 16, 2026
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 14, 2027
    The maintenance fee for HIV protease inhibitors (US 9,079,834) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for HIV protease inhibitors (US 9,133,157) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 1 fee due Apr 27, 2027
    The maintenance fee for Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase (US 9,168,248) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
  • 1 fee due May 17, 2027
    The maintenance fee for Sulfonamides as HIV protease inhibitors (US 9,187,415) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,696,222Indole derivatives as CRTH2 receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,442,7162-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,705,035Indoline amide derivatives as EP4 receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,968,578Indole amide derivatives as EP4 receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,928,091Cathepsin cysteine protease inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,003,661Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,158,671Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,969,394Thiophenecarboxamide Derivatives as EP4 Receptor Ligands
In force
 · High confidence
In forceHigh confidence
US 8,013,159Quinoline Derivatives as EP4 Antagonists
In force
 · High confidence
In forceHigh confidence
US 8,642,799Cysteine protease inhibitors for the treatment of parasitic diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
Also on record, not counted in the 16: 18 patents in force now held by others · 21 lapsed for an unpaid fee · 30 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited